PMID- 27739418
OWN - NLM
STAT- MEDLINE
DCOM- 20170504
LR  - 20190606
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 22
DP  - 2016 Oct 14
TI  - Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in 
      Hepatocellular Carcinoma.
PG  - 3694-3704
AB  - BACKGROUND Hepatocellular carcinoma (HCC) causes many deaths worldwide every 
      year, especially in Asia. It is characterized by high malignancy, recurrence, and 
      short survival time. Inflammation is closely related to the initiation and 
      development of HCC. Tumor necrosis factor-alpha (TNF-alpha), an essential inflammatory 
      mediator, has been studied as a potential therapy target in many cancers. 
      However, its potential role in HCC diagnosis and therapy is still unclear. 
      MATERIAL AND METHODS In our study, we detected the TNF-alpha expression in both human 
      HCC tumor tissue and HCC cell lines HepG2 and HuH7. Then, we detected the effect 
      of anti-TNF-alpha treatment and it synergistic function with 5-FU in an HCC xenograft 
      mouse model and in HCC cell lines. RESULTS Survival analysis and Cox regression 
      analysis based on 97 HCC patients indicated that a high level of TNF-alpha is an 
      independent predictor of poor survival in HCC patients. Anti-TNF-alpha treatment by 
      infliximab synergizes with Fluorouracil (5-FU) by promoting apoptosis of HCC 
      tumor cells through complement-dependent cytotoxicity (CDC) and 
      antibody-dependent cellular cytotoxicity (ADCC) effects. CONCLUSIONS Based on 
      these data, we conclude that anti-TNF-alpha treatment could be a good way to increase 
      the effect of classic chemotherapy of HCC patients, especially for the patients 
      who have modest response to classic chemotherapy, such as 5-FU. TNF-alpha could also 
      be used as a biomarker to help in early diagnosis of HCC.
FAU - Wang, Hongmei
AU  - Wang H
AD  - Department of Clinical Laboratory Medicine, The First Affiliated Hospital of 
      Liaoning Medical University, Jinzhou, Liaoning, China (mainland).
FAU - Liu, Jianmin
AU  - Liu J
AD  - Allergy and Clinical Immunology Research Center, The First Affiliated Hospital of 
      Liaoning Medical University, Jinzhou, Liaoning, China (mainland).
FAU - Hu, Xuemei
AU  - Hu X
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Liaoning 
      Medical University, Jinzhou, Liaoning, China (mainland).
FAU - Liu, Shanshan
AU  - Liu S
AD  - Department of Clinical Laboratory Medicine, The First Affiliated Hospital of 
      Liaoning Medical University, Jinzhou, Liaoning, China (mainland).
FAU - He, Baojun
AU  - He B
AD  - Department of Clinical Laboratory Medicine, The First Affiliated Hospital of 
      Liaoning Medical University, Jinzhou, Liaoning, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20161014
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Carcinoma, Hepatocellular/genetics/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Female
MH  - Fluorouracil/therapeutic use
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Hep G2 Cells
MH  - Humans
MH  - Infliximab/therapeutic use
MH  - Liver Neoplasms/genetics/metabolism
MH  - Male
MH  - Mice
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/genetics
MH  - Prognosis
MH  - Tumor Necrosis Factor-alpha/metabolism/*therapeutic use
MH  - Xenograft Model Antitumor Assays
PMC - PMC5067111
COIS- of conflict of interest None.
EDAT- 2016/10/16 06:00
MHDA- 2017/05/05 06:00
PMCR- 2016/10/14
CRDT- 2016/10/15 06:00
PHST- 2016/10/15 06:00 [entrez]
PHST- 2016/10/16 06:00 [pubmed]
PHST- 2017/05/05 06:00 [medline]
PHST- 2016/10/14 00:00 [pmc-release]
AID - 899773 [pii]
AID - 10.12659/msm.899773 [doi]
PST - epublish
SO  - Med Sci Monit. 2016 Oct 14;22:3694-3704. doi: 10.12659/msm.899773.